ClinicalTrials.gg
CompletedNCT01526382PiCCOUpdated May 4, 2015

Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome

A Phase 1/2 interventional study of PiCCO monitoring (PULSION) and central venous catheter in Septic Shock and Acute Respiratory Distress Syndrome, sponsored by Jinhua Central Hospital. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-05-04.

Sponsored by Jinhua Central Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.

Enrollment
11th of 62
350 · median 72
Started
2012
with 3 others
Phase 1/2
4 of 89
none open now
Registered
3rd of 89
by date
Lead sponsor
2 of 89
Jinhua Central Hospital

Among the 89 studies in Shock, Septic with a site in China, this one is the 11th largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 1/2, and was the 3rd registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Shock, Septic with a site in China, or all of them as a file.
02

Study summary

PiCCO has been widely used in critical care settings for several decades. Together with pulmonary artery catheter, it is regarded as the important tool for guiding fluid management in patients with shock or acute respiratory distress syndrome. However, its effects on patients' outcome remain untested. The investigators study is a pilot study that is designed to test whether the use of PiCCO will improve patients' outcome, as compared to those without PiCCO monitoring.

Read the detailed description

PiCCO comprises techniques of pulse contour analysis and transpulmonary thermodilution, and can provide important information on hemodynamics and pulmonary functions. It has been widely used in critical care settings for several decades. Together with pulmonary artery catheter (PAC), it is regarded as the important tool for guiding fluid management in patients with shock or acute respiratory distress syndrome. During last two decades, many well designed clinical trials have been conducted to see whether the use of PAC would benefit patient outcome. The result consistently showed that PAC added no benefit in terms of mortality, ICU length of stay, organ failure free survival days, and the length of mechanical ventilation. Since PiCCO is relatively new to PAC, and its effects on patients' outcome remain untested. The investigators study is a pilot study that is designed to test whether the use of PiCCO will improve patients' outcome, as compared to those without PiCCO monitoring.

03

Conditions studied

  • Septic Shock
  • Acute Respiratory Distress Syndrome

Keywords

  • septic shock
  • acute respiratory distress syndrome
  • transpulmonary thermodilution technique
  • mortality
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients were included if they were diagnosed with Shock, Acute respiratory distress syndrome (ARDS), or both.

Shock was defined by the presence 4 criteria:

  • Heart rate of at least 90/min;
  • A respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower or the use of mechanical ventilation;
  • The use of vasopressors to maintain a systolic blood pressure of at least 90mmHg despite fluid resuscitation, low dose of dopamine (≤ 5 μg/kg per minute), or dobutamine;
  • at least 1 of 3 signs of hypoperfusion (urine output \< 0.5mL/kg of body weight per hour for 1 hour or more; neurologic dysfunction defined by confusion, psychosis, or a Glasgow coma scale score of ≤ 6; plasma lactate higher than the value).

Acute respiratory distress syndrome:

  • the presence of acute decrease in PaO2/FIO2 to 200mmHg or lower,
  • bilateral pulmonary infiltrates or a chest radiograph consistent with edema;
  • no clinical evidence of left atrial hypertension; and requirement for positive pressure ventilation.

Exclusion criteria

Exclusion Criteria:

  • Patients were moribund.
  • signed do-not-resuscitation odor.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
350 participants (actual)

Study arms

  • Active comparator
    intervention arm

    patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions

    Device: PiCCO monitoring (PULSION)

  • Placebo comparator
    control arm

    Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.

    Procedure: central venous catheter

Interventions

  • DevicePiCCO monitoring (PULSION)

    Patients are monitored with PiCCO system.

    Also known as: PiCCO (pulsion medical system, PULSION PiCCO plus)

  • Procedurecentral venous catheter

    patients in this arm can receive central venous catheter

06

What researchers measure

Primary outcomes

  1. 30 day mortality

    death from any cause before day 30

    Time frame: 30 days

Secondary outcomes

  1. 14 day mortality

    patients were followed up for 14 days

    Time frame: 14 days

  2. ICU length of stay

    the time from ICU admission to ICU discharge or death

    Time frame: up to 30 days

  3. days on mechanical ventilation

    days during which the patients are on mechnical ventilation: The criteria for termination of mechanical ventilation: a cooperative patient, recovery from primary disease, hemodynamically stable, adequate and strong cough reflex, positive end-expiratory pressure \<5 cmH2O, pressure support \<10 cmH2O and the spontaneous breathing trial is successfully passed.

    Time frame: up to 30 days

  4. days of vasoactive agents support

    days during which vasoactive agents are used: The sum of the number of days with one or more vasoactive agents to maintain a mean arterial pressure \>60 mmHg

    Time frame: up to 30 days

  5. ICU free survival days during 30-day period

    ICU free survival days during 30-day period

    Time frame: 30 days

  6. mechanical ventilation free survival days during 30-day period

    mechanical ventilation free survival days during 30-day period

    Time frame: 28 days

07

Study locations

2 sites
  • department of critical care medicine, Jinhua central hospital
    Jinhua, Zhejiang 321000, China
  • Traditional Chinese Medical hospital of Jinhua City
    Jinhua, Zhejiang 321000, China
08

References and documents

Publications

  • Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, Boulain T, Lefort Y, Fartoukh M, Baud F, Boyer A, Brochard L, Teboul JL; French Pulmonary Artery Catheter Study Group. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2003 Nov 26;290(20):2713-20. doi: 10.1001/jama.290.20.2713. PubMed 14645314 ↗
  • Zhang Z, Xu X, Yao M, Chen H, Ni H, Fan H. Use of the PiCCO system in critically ill patients with septic shock and acute respiratory distress syndrome: a study protocol for a randomized controlled trial. Trials. 2013 Feb 1;14:32. doi: 10.1186/1745-6215-14-32. PubMed 23374652 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2012
First posted
Feb 3, 2012
Start
Jan 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
May 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01526382
Lead sponsor
Jinhua Central Hospital
Responsible party
Zhongheng Zhang (principal investigator, Jinhua Central Hospital) — Principal investigator
First posted
Feb 3, 2012
Start date
Jan 2012
Primary completion
Jun 2014
Completion
Jun 2014
Last update
May 4, 2015

Study contacts

Zhongheng Zhang, MD
study chair · Jinhua Municipal Central Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion